Table 1 Baseline patient characteristics (n = 24).

From: Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy

Median age (range)

50.1 years (31.9–74.4 years)

Race

Non-Hispanic Caucasian

16/24 (66.7%)

African–American

6/24 (25%)

Hispanic Caucasian

2/24 (8.3%)

Stage prior to treatment (as per AJCC 7th edition)

II

13/24 (54.2%)

III

11/24 (45.8%)

Nodal status prior to treatment

N0

8/24 (33.3%)

N1

10/24 (41.7%)

N2

6/24 (25%)

Genetic testing

Performed

20/24 (83.3%)

 No germline mutation detected

18/20

 Germline mutation detected

2/20 (both had PALB2 mutation)

Not performed

4/24 (16.7%)

Prior neoadjuvant chemotherapy

Dose dense doxorubicin + cyclophosphamide followed by paclitaxel

15/24 (62.5%)

Docetaxel + doxorubicin + cyclophosphamide

7/24 (29.2%)

Ixabepilone + doxorubicin + cyclophosphamide

1/24 (4.2%)

Ixabepilone + cetuximab + doxorubicin + cyclophosphamide

1/24 (4.2%)

Back to article page